refractive outcomes with toric icl implants chief author: dr. d.ramamurthy co – author: dr....
TRANSCRIPT
![Page 1: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/1.jpg)
REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS
CHIEF AUTHOR : Dr. D.RAMAMURTHYCO – AUTHOR : Dr. R.CHITRA
The authors have no financial interest in the subject matter of this poster
THE EYE FOUNDATIONCOIMBATORE & TIRUPURINDIA
![Page 2: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/2.jpg)
TORIC ICL – REFRACTIVE OUTCOMES
PURPOSE
TO STUDY THE EFFICACY AND PREDICTABILITY
OF THE FIRST 100 CONSECUTIVE
TORIC ICL IMPLANTS
![Page 3: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/3.jpg)
TORIC ICL – REFRACTIVE OUTCOMES
MATERIALS & METHODS
NUMBER OF PATIENTS - 69
(MALE – 40, FEMALE - 29)
NUMBER OF EYES - 100 (UNILATERAL – 38, BILATERAL- 31)
AGE GROUP - 18 TO 48
PERIOD OF FOLLOW-UP - 2 TO 24 MONTHS
STUDY PERIOD - MAY 2007 TO DEC 2009
![Page 4: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/4.jpg)
TORIC ICL – REFRACTIVE OUTCOMES
INCLUSION CRITERIA
AGE ABOVE 18 YEARS WITH STABLE REFRACTION FOR ATLEAST ONE YEAR
NOT IN THE RANGE FOR LASER VISION CORRECTION CORNEAL THICKNESS < 480 µ RESIDUAL BED < 300 µ ASTIGMATISM > 3 D SPHERICAL EQUIVALENT > 12 D ANY EVIDENCE OF FORME FRUSTE KERATOCONUS
AC DEPTH > 2.8 mm
OTHERWISE NORMAL EYES (MILD TO MODERATE MYOPIC MACULAR DEGENARATION NOT CONSIDERED AS AN EXCLUSION)
![Page 5: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/5.jpg)
TORIC ICL – REFRACTIVE OUTCOMES
PROCEDURE
SIZING BASED ON CALIPERS & ORBSCAN W to W MEASUREMENT
YAG IRIDOTOMY 1 WEEK BEFORE SURGERY
TOPICAL ANAESTHESIA
AXIS MARKING WITH PATIENT SITTING IN OPERATION THEATRE
TEMPORAL 3.2 mm INCISION
![Page 6: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/6.jpg)
TORIC ICL – REFRACTIVE OUTCOMES
VISUAL OUTCOMES
VISUAL ACUITY
PRE-OP
BCVA
(No of Eyes)
POST OP UCVA AT
FINAL FOLLOW UP
(No of Eyes)
POST OP BCVA AT FINAL
FOLLOW UP
(No of Eyes)
6/6 36 36 38
6/9 48 45 43
6/12 5 12 8
6/18 7 5 7
< 6/60 4 2 4
05
101520253035404550
6/6 6/9 6/12 6/18 <6/60
PRE-OP BCVA
POST-OPUCVA @ FINALFOLLOW UP
POST-OPBCVA @ FINALFOLLOW UP
No
of
EY
ES
VISUAL ACUITY
![Page 7: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/7.jpg)
TORIC ICL – REFRACTIVE OUTCOMES
POWER RANGE CORRECTED
SPHERICAL RANGE - 1.50 TO – 19.00
CYLINDER RANGE - 1.25 TO – 5.5
SPHERICAL EQUIVALENT RANGE 2.75 TO 20
![Page 8: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/8.jpg)
TORIC ICL – REFRACTIVE OUTCOMES
.
RESIDUAL POWER IN SPH EQUIVALENT
BETWEEN 0.25 & 0.5 21 EYES
BETWEEN 0.5 & 1 3 EYES
> 1 1 EYE
![Page 9: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/9.jpg)
TORIC ICL – REFRACTIVE OUTCOMES
RESIDUAL CYLINDER
BETWEEN - 0.25 & - 0.5 2 EYES
BETWEEN - 0.5 & - 1.0 9 EYES
> - 1 5 EYES
![Page 10: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/10.jpg)
TORIC ICL – REFRACTIVE OUTCOMES
RESULTS
VISUAL ACUITY COMPARISON
IMPROVED
(1 LINE)
DIMINISHED
(1 LINE)
IMPROVED OR DIMISHED BY >
1 LINE
CHANGE
<
1 LINE
PRE OP BCVA Vs POST OP UCVA
5 EYES 12 EYES 0 83 EYES
PRE OP BCVA Vs POST OP BCVA
10 EYES 2 EYES 0 88 EYES
![Page 11: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/11.jpg)
TORIC ICL – REFRACTIVE OUTCOMES
COMPLICATIONS PIGMENT DEPOSITS ON ICL & ENDOTHELIUM : 31
EYES
POST OP RAISED IOP CONTROLLED WITH MEDICATION : 7 EYES
LOW VAULT : 8 EYES
EXCESSIVE VAULT: 4 EYES
REPEAT IRIDOTOMY IN POST OP PERIOD : 2 EYES
LOCALIZED ANTERIOR SUBCAPSULAR OPACITY : 1 EYE
ICL REPOSITIONING FOR INAPPROPRIATE AXIS : 2 EYES
HIGH VAULT
![Page 12: REFRACTIVE OUTCOMES WITH TORIC ICL IMPLANTS CHIEF AUTHOR: Dr. D.RAMAMURTHY CO – AUTHOR: Dr. R.CHITRA The authors have no financial interest in the subject](https://reader036.vdocuments.net/reader036/viewer/2022070413/5697bff11a28abf838cbb67b/html5/thumbnails/12.jpg)
TORIC ICL – REFRACTIVE OUTCOMES
CONCLUSION
TORIC ICL SEEMS TO BE A RELIABLE, PREDICTABLE MODALITY
FOR CORRECTING MYOPIC ASTIGMATISM WHICH ARE NOT AMENABLE TO LASER VISION CORRECTION